Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.

Leukemia research·2013
Same author

Effects of 3, 5, 3'-triiodothyronine (t3) and follicle stimulating hormone on apoptosis and proliferation of rat ovarian granulosa cells.

The Chinese journal of physiology·2013
Same author

Cardiogenic shock from acute ST-segment elevation myocardial infarction induced by severe multivessel coronary vasospasm.

European heart journal·2013
Same author

[Comparative study on effects of electroacupuncture stimulation of Shenmen (HT 7) and Taiyuan (LU 9) on P 300 of event-related potentials and brain electrical activity mapping in healthy young adults].

Zhen ci yan jiu = Acupuncture research·2013
Same author

MiR-215 modulates gastric cancer cell proliferation by targeting RB1.

Cancer letters·2013
Same author

Low glucose utilization and neurodegenerative changes caused by sodium fluoride exposure in rat's developmental brain.

Neuromolecular medicine·2013
Same journal

Malignant epithelial states drive immune dysfunction in ampulla of Vater carcinoma.

Biomarker research·2026
Same journal

TAF15-mediated m5C modification of MTHFD2 RNA reveals a novel therapeutic target for IDH mutant gliomas.

Biomarker research·2026
Same journal

Biology-aligned cervical cancer screening: target-centric biomarkers and next-generation diagnostic platforms.

Biomarker research·2026
Same journal

CD163<sup>+</sup> macrophages coordinate erythroblastic Island formation and iron metabolism to enable glucocorticoid-induced erythropoiesis.

Biomarker research·2026
Same journal

Spatial transcriptomics reveals compartment-specific cytotoxic T cell crosstalk with AT2 and goblet cells in advanced COPD.

Biomarker research·2026
Same journal

Cell death crosstalk in NET-Driven inflammation: mechanisms, disease contexts, and therapeutic perspectives.

Biomarker research·2026
See all related articles

Related Experiment Video

Updated: Feb 27, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.0K

Engineering CAR-T cells.

Cheng Zhang1, Jun Liu1, Jiang F Zhong2

  • 1Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037 People's Republic of China.

Biomarker Research
|June 28, 2017
PubMed
Summary
This summary is machine-generated.

Chimeric antigen receptor (CAR-T) cell therapy shows promise for blood cancers and is being explored for solid tumors. This review covers CAR-T cell structure, production tools, and current challenges for wider adoption.

Keywords:
CAR-T cellsChimeric antigen receptor redirected T cellsEvolutionProductionStructureViral vector

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Related Experiment Videos

Last Updated: Feb 27, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Area of Science:

  • Immunotherapy
  • Cellular Therapy
  • Oncology

Background:

  • Chimeric antigen receptor (CAR-T) cell therapy has shown significant success in treating B cell malignancies.
  • This therapy involves genetically modifying a patient's or donor's T cells to target cancer cells.
  • CAR-T cell applications are expanding into other hematologic and solid tumors.

Purpose of the Study:

  • To review the structure and evolution of chimeric antigen receptors.
  • To discuss the tools and methods used in the production of CAR-T cells.
  • To identify and address the challenges hindering widespread CAR-T cell therapy adoption.

Main Methods:

  • Literature review of CAR-T cell technology.
  • Analysis of CAR receptor design and engineering.
  • Examination of CAR-T cell manufacturing processes.
  • Discussion of clinical and technical hurdles.

Main Results:

  • CAR-T cell therapy has demonstrated efficacy in specific cancer types.
  • Various tools and techniques are available for CAR-T cell generation.
  • Significant challenges remain in optimizing CAR-T cell therapy for broader application.

Conclusions:

  • CAR-T cell therapy is a rapidly advancing field with transformative potential.
  • Further research and development are crucial to overcome existing challenges.
  • Widespread adoption of CAR-T cell therapy requires addressing manufacturing, safety, and efficacy issues.